Pharmaceutical - USA, CNS Diseases

Filter

Current filters:

USACNS Diseases

Popular Filters

Sarepta receives new FDA guidance on data needed for eteplirsen's NDA in Duchenne Muscular Dystrophy

Sarepta receives new FDA guidance on data needed for eteplirsen's NDA in Duchenne Muscular Dystrophy

28-10-2014

Rare and infectious disease specialist Sarepta provided an update on its discussions with the US Food…

CNS DiseaseseteplirsenPharmaceuticalRegulationSarepta TherapeuticsUSA

GW Pharmaceuticals granted orphan designation by the EMA for Epidiolex

GW Pharmaceuticals granted orphan designation by the EMA for Epidiolex

22-10-2014

Cannabinoid product specialist GW Pharmaceuticals has been granted orphan designation by the European…

CNS DiseasesepidiolexGW PharmaceuticalsPharmaceuticalResearchUSA

FDA accepts NDA filing for Lundbeck and Otsuka's brexpiprazole

FDA accepts NDA filing for Lundbeck and Otsuka's brexpiprazole

24-09-2014

The US Food and Drug Administration has accepted the filing for review of brexiprazole for the treatment…

CNS DiseasesLundbeckOtsukaPharmaceuticalRegulationUSA

Avanir shares jump 85% on positive AVP-923 clinical trial results

Avanir shares jump 85% on positive AVP-923 clinical trial results

16-09-2014

US CNS specialist Avanir Pharmaceuticals has announced positive results from the Phase II clinical trial…

AvanirAVP-923CNS DiseasesPharmaceuticalResearchUSA

MS market to reach $20 billion in 2023 boosted by five new therapies

MS market to reach $20 billion in 2023 boosted by five new therapies

08-08-2014

The forecast launch of five immunomodulatory therapies for relapsing forms of multiple sclerosis will…

CNS DiseasesEuropeImmunosuppressantsJapanMarkets & MarketingMSPharmaceuticalUSA

Biogen and AbbVie release Phase III data for MS treatment

Biogen and AbbVie release Phase III data for MS treatment

17-06-2014

US biotech firm Biogen Idec and US drugmaker AbbVie have announced positive top-line results from the…

AbbVieBiogen IdecCNS DiseasesdaclizumabPharmaceuticalResearchUSA

US FDA grants Edison Pharmaceuticals’ EPI-743 orphan status for Leigh Syndrome

US FDA grants Edison Pharmaceuticals’ EPI-743 orphan status for Leigh Syndrome

09-06-2014

The US Food and Drug Administration has granted orphan drug status to privately-held US pharma company…

CNS DiseasesEdison PharmaceuticalsEPI-743PharmaceuticalRegulationUSA

Pfizer agrees to pay $325 million over Neurontin

Pfizer agrees to pay $325 million over Neurontin

03-06-2014

US pharma giant Pfizer has agreed a $325 million settlement over a trial regarding the marketing of Neurontin…

CNS DiseasesLegalNeurontinPfizerPharmaceuticalUSA

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Back to top